Ebenbuild
Ebenbuild is a Munich-based deep-tech healthcare company that builds AI-enabled patient-specific digital lung twins for two markets: hospital ICUs (Aerogram clinical decision support for ventilation) and pharmaceutical/biotech/medtech firms (Twinhale in silico drug delivery trials).
- Company typePrivate
- Founded2019
- HeadquartersMunich, Germany
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Ebenbuild does
Ebenbuild GmbH is a Munich-based deep-tech healthcare company founded in 2019 that develops patient-specific digital twins of the human lung using a combination of physics-based modeling (computational fluid dynamics, tissue mechanics) and AI/ML applied to standard CT imaging. The platform addresses two distinct use cases: Aerogram, a clinical decision support software under development for ICU clinicians to optimize mechanical ventilation settings for patients with acute respiratory distress syndrome (ARDS) and other lung complications, and Twinhale, an in silico trial software launched in July 2025 that enables pharmaceutical, biotech, and medtech companies to simulate regional pulmonary drug deposition for inhaled therapeutics and inhalation devices. The technology has been validated against 3D SPECT/CT imaging with a reported 0.95 correlation coefficient for lobar deposition predictions, and supporting work has been published in Nature Communications Medicine and the Journal of Applied Physiology.
The company operates a B2B enterprise sales motion, with named customers including PARI Pharma, Pieris Pharmaceuticals (now Pavella Therapeutics), HCMed Innovations, Crux Product Design, Avalyn Pharma, and RNHale. Revenue mechanics combine project-based in silico trial services (delivered within roughly two weeks of engagement) with software licensing of Twinhale on multi-year contracts; pricing is quote-based and not publicly disclosed. Aerogram is positioned for future recurring subscription licensing to hospitals and ICUs once regulatory milestones are reached.
Ebenbuild is venture-backed, having raised approximately €2.5M in seed funding (Bayern Kapital and High-Tech Gründerfonds, March 2022), a €900K BMBF grant as part of the UBIC consortium (November 2023), and a €2.3M EIC Accelerator grant (July 2025) with a commitment from the EIC Fund to invest up to €10M in future equity rounds. The team of around 17 includes four co-founders (CEO Dr. Kei Müller, CTO Dr. Jonas Biehler, Chief Architect/VP Engineering Dr. Karl-Robert Wichmann, and Chief Scientific Advisor Prof. Wolfgang Wall) plus a Chief Commercial Officer, and is chaired by Charles A. Taylor, PhD, founder of HeartFlow. The company is pursuing US market entry through the German Accelerator Life Sciences program and is aligning its offering with FDA Model-Informed Drug Development and EMA New Approach Methodologies frameworks.
Ebenbuild firmographics
Firmographics- Name
- Ebenbuild
- Legal name
- Ebenbuild GmbH
- Website
- https://ebenbuild.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ebenbuild is a Munich-based deep-tech healthcare company that builds AI-enabled patient-specific digital lung twins for two markets: hospital ICUs (Aerogram clinical decision support for ventilation) and pharmaceutical/biotech/medtech firms (Twinhale in silico drug delivery trials).
- Ownership category
- akta.pro rank
Ebenbuild industry classification
Industry- Product category
- Computational Pulmonology Software
- NAICS
- Software Publishers (5132)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Healthcare & Clinical Simulation (imaging, radiotherapy planning, patient twins) (HDAGAEAL)
- akta.pro secondary industries
- Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand) (HDAGAEAB), Nebulizers & Aerosol Drug Delivery Systems (HLAHAIAJ), Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management (HLAKANAM)
Keywords
Where Ebenbuild is headquartered
LocationHeadquarters
- HQ city
- Munich
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Ebenbuild business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Twinhale Software Licensing: Revenue from licensing in silico trial software to pharmaceutical and medtech companies for respiratory drug development. Revenue-generating projects already in progress with pilot studies for PARI Pharma and Pieris Pharmaceuticals.
- In Silico Trial Services: Customized in silico trials conducted for clients, delivering quantitative evidence on regional drug deposition within 2 weeks of engagement. Project-based engagements with pharmaceutical companies.
- Aerogram Clinical Software: Regulated clinical application in development for intensive care decision-making. Future product for optimizing mechanical ventilation in patients with lung complications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom In Silico Trial Projects |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Ebenbuild product offering
Product offeringCore offering
Ebenbuild develops and sells an AI-enabled digital lung twin platform comprising two products: Aerogram, a cloud-based clinical decision support system that builds patient-specific lung digital twins from routine CT scans to optimize mechanical ventilation in ICU patients, and Twinhale, in silico trial software that enables pharmaceutical and medtech companies to simulate pulmonary drug delivery and predict regional aerosol deposition in virtual patient cohorts. The underlying platform combines physics-based computational fluid dynamics, tissue mechanics, and AI/ML to simulate airflow, aerosol transport, and drug deposition across the entire respiratory system.
Product overview
Ebenbuild offers a digital twin platform technology comprising two main products: Aerogram and Twinhale. Aerogram is a cloud-based clinical decision support system for intensive care that generates patient-specific digital twins from CT scans to optimize mechanical ventilation settings. Twinhale is an in silico trial software application for pharmaceutical and medtech companies to simulate pulmonary drug delivery and predict aerosol deposition patterns. Both products share the same core physics-based modeling engine that combines computational fluid dynamics, tissue mechanics, and AI to create patient-specific lung simulations.
Differentiator
Problem solved
Functional benefit
Brands
- Aerogram: Clinical decision support software that creates patient-specific digital twins from routine imaging to help clinicians optimize ventilation settings for ICU patients
- Twinhale
Products and services
- Aerogram Cloud-based clinical decision support software that creates patient-specific digital twins from routine CT imaging to simulate how individual lungs respond to different ventilator settings, providing objective guidance for personalized protective ventilation in ICU patients with ARDS and acute lung complications.
- Twinhale In silico trial software for pulmonary drug delivery that enables pharmaceutical and medtech companies to simulate drug deposition in virtual patient cohorts, supporting dose selection, formulation development, device configuration optimization, and trial planning by predicting where inhaled drugs deposit across the entire human lung.
Quantifiable outcome
- Lobar deposition predictions achieved correlation coefficient of 0.95 with experimental 3D SPECT/CT imaging data
- +3 more outcomes
Companies that use Ebenbuild
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
Ebenbuild technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature4 records
Ebenbuild partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- PARI PharmacorePilot study collaboration for in silico pulmonary drug delivery simulation. PARI is a leading nebulizer manufacturer; study focused on realistic transient aerosol parameters for lung deposition prediction.
- Pieris Pharmaceuticals (now Pavella Therapeutics, Inc.)coreTwinhale simulation technology used in Nature Communications publication demonstrating PRS-220 inhaled therapeutic potential for IPF. Digital twins provided precise predictions of aerosol deposition patterns in fibrotic lung tissue.
- German Accelerator Life Sciences U.S.coreAccepted into German Accelerator's Life Sciences U.S. market access program supported by Federal Ministry for Economic Affairs and Energy. Program advances digital lung twin technology in US by refining regulatory and market strategies.
- BreatheAssist (FAU Nürnberg-Erlangen)minorBMBF-funded project collaboration developing interface between Ebenbuild's digital analysis software and innovative medical technology from BreatheAssist.
- UBIC Consortium (University Hospital Schleswig-Holstein, University Hospital Augsburg, University Hospital Carl Gustav Carus Dresden, University Hospital RWTH Aachen, University Medical Center Mannheim)coreBMBF-funded consortium (€1.8M total, €900K to Ebenbuild) for Personalized Lung Twins for ARDS treatment. Clinical partners provide heterogeneous patient data for algorithm training and validation.
- Open Source Image Consortium (OSIC)coreJoined consortium fighting against idiopathic pulmonary fibrosis, fibrosing interstitial lung diseases, and other respiratory diseases. OSIC provides access to CT data from IPF patients for digital twin development.
- Daylight DesignminorUX design partnership for product interface development. Daylight created case study showcasing user experience design collaboration.
- HCMed InnovationscoreCollaboration on adaptive breath-actuated mesh nebulisers using in silico evidence to demonstrate optimization of lung deposition.
- Crux Product DesigncorePartnership on enhanced approach to predicting site-specific inhaled drug deposition via in-vitro and in-silico data fusion.
- Avalyn PharmacoreCollaboration on inhaled drug delivery development. Study details not yet public.
- RNHalecorePartnership for respiratory drug delivery collaboration.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Ebenbuild competitors and assessment
Company assessmentBroad incumbents
- Dassault Systèmes (Living Heart Project): Dassault Systèmes provides broad engineering simulation platforms including the Living Heart Project, a multi-partner cardiac digital twin initiative. Comparable as a physics-based simulation vendor expanding into organ-level digital twins for life sciences R&D.
- Ansys: Ansys provides multiphysics simulation software widely used in engineering and increasingly in life sciences (computational fluid dynamics for respiratory and cardiovascular R&D). Comparable as an incumbent computational simulation platform whose tools overlap with Ebenbuild's physics-based lung modeling engine.
- Schrödinger: Schrödinger operates a physics-based computational platform for drug discovery and materials science used by major pharmaceutical companies. Comparable to Ebenbuild in selling computational simulation software to pharma R&D, but at much broader scope and scale.
Direct peers
- HeartFlow: HeartFlow builds patient-specific digital twins of the heart from CT imaging to support clinical decision-making. It is the closest analogue to Ebenbuild's lung digital twin platform and shares Chairman Charles A. Taylor, who founded HeartFlow.
- Q Bio: Q Bio builds a "Digital Twin" of the whole patient from whole-body MRI to support preventive clinical decisions. Comparable to Ebenbuild in building organ/patient-level digital twins from imaging data for clinical decision support.
- Twin Health: Twin Health applies a whole-body digital twin platform to manage and reverse chronic metabolic disease. Comparable as a vertically integrated digital twin platform combining AI with patient-specific physiology for both clinical and research use.
- Unlearn.AI: Unlearn develops AI-generated digital twin "prognostic covariates" used to run faster, smaller clinical trials. Comparable to Ebenbuild's Twinhale in using patient-specific digital twins to support pharmaceutical R&D and trial design.
Emerging players
- CytoReason: CytoReason builds computational models of the immune system used by pharmaceutical companies to accelerate drug development. Comparable to Ebenbuild in selling AI/computational models into pharma R&D pipelines as decision-support tools.
- Insilico Medicine: Insilico Medicine uses AI and computational modeling for end-to-end drug discovery and runs in silico trials. Comparable to Ebenbuild in applying AI-driven simulation to pharmaceutical R&D, though with a broader therapeutic scope than respiratory.
- Respira Labs: Respira Labs develops AI-based respiratory monitoring and diagnostics (wearable-based lung function assessment). Comparable as a respiratory-focused digital health company leveraging AI for lung assessment, though focused on monitoring rather than simulation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Ebenbuild social profiles
Digital presenceEbenbuild financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ebenbuild leadership team
Management profileNumber of profiles
Profiles14 records
Ebenbuild funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ebenbuild M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ebenbuild
What does Ebenbuild do?
Ebenbuild develops and sells an AI-enabled digital lung twin platform comprising two products: Aerogram, a cloud-based clinical decision support system that builds patient-specific lung digital twins from routine CT scans to optimize mechanical ventilation in ICU patients, and Twinhale, in silico trial software that enables pharmaceutical and medtech companies to simulate pulmonary drug delivery and predict regional aerosol deposition in virtual patient cohorts. The underlying platform combines physics-based computational fluid dynamics, tissue mechanics, and AI/ML to simulate airflow, aerosol transport, and drug deposition across the entire respiratory system.
Is Ebenbuild a public or private company?
Ebenbuild is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ebenbuild founded?
Ebenbuild was founded in 2019. It employs 11 to 50 people.
Where is Ebenbuild based?
Ebenbuild is headquartered in Munich, Germany, in the Europe region.
How does Ebenbuild make money?
Three revenue lines are on record. Twinhale Software Licensing is the primary driver. The others are in Silico Trial Services and aerogram Clinical Software.
Who are Ebenbuild's main competitors?
Broad incumbents on record are Dassault Systèmes (Living Heart Project), Ansys and Schrödinger. Direct peers are HeartFlow, Q Bio, Twin Health and Unlearn.AI. Emerging players are CytoReason, Insilico Medicine and Respira Labs.
Does Ebenbuild have an API?
No public API is recorded for Ebenbuild.
What industry is Ebenbuild in?
Ebenbuild's product category is Computational Pulmonology Software. Its primary akta.pro industry code is HDAGAEAL, Healthcare & Clinical Simulation (imaging, radiotherapy planning, patient twins), with a secondary code of HDAGAEAB, Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand). Its NAICS code is 5132 and its SIC code is 3841.